| Abstract | BACKGROUND: This study evaluated the feasibility, toxicity, response rate and survival of neoadjuvant superselective intra-arterial infusion of high dose carboplatin in advanced head and neck cancer. METHODS: Forty-six patients with primary head and neck squamous cell carcinoma received 3 cycles of intra-arterial carboplatin (300 to 350 mg/m2 per cycle every 2 weeks), followed by radiotherapy or surgery plus radiotherapy. RESULTS: No complications or severe toxicity occurred. Sixteen patients (35%) were complete responders, 20 (43%) partial responders while 10 (22%) did not respond to treatment. After completion of the multimodality treatment, 38/46 patients (83%) were complete responders. After a 5-year follow-up period, 18/46 patients (39%) are alive and disease-free, 3 (6,5%) have died of a second primary tumor and 25 (54.5%) have died of the disease. CONCLUSION: Intra-arterial carboplatin induction chemotherapy is a safe, well-tolerated technique that discriminates between responders and non-responders and so may have prognostic significance in planning further integrated treatments aimed to organ preservation for advanced head and neck carcinomas. |
| Authors | Giulia Bertino, Marco Benazzo, Patrizia Gatti, Gianni Bernardo, Franco Corbella, Carmine Tinelli, Federico Zappoli, Eugenio Mira
(Affiliation: Department of Otolaryngology, University of Pavia--IRCCS Policlinico S Matteo, Pavia, Italy. giulia.bertino at tin.it)
|
| Journal | BMC cancer
(BMC Cancer)
Vol. 7
Pg. 62
( 2007)
ISSN: 1471-2407 England |
| PMID | 17428336
(Publication Type: Clinical Trial, Journal Article)
|
| Chemical References |
- Antineoplastic Agents
- Carboplatin
|
| Topics |
- Adult
- Aged
- Antineoplastic Agents
(administration & dosage, adverse effects, therapeutic use)
- Carboplatin
(administration & dosage, adverse effects, therapeutic use)
- Carcinoma, Squamous Cell
(drug therapy, radiotherapy, surgery)
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Female
- Follow-Up Studies
- Head and Neck Neoplasms
(drug therapy, radiotherapy, surgery)
- Humans
- Infusions, Intra-Arterial
- Male
- Middle Aged
- Treatment Outcome
|
